Drug Profile


Alternative Names: mGluR2/3 antagonist - Roche; R-1578; RG-1578; RO-4995819; RO4995819/F05

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Roche
  • Class Amines; Antidementias; Antidepressants; Pyrazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 antagonists; Metabotropic glutamate receptor 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dementia; Major depressive disorder

Most Recent Events

  • 28 Jan 2015 Discontinued - Phase-I for Major depressive disorder (Combination therapy, In volunteers) in France (PO)
  • 28 Jan 2015 Discontinued - Phase-I for Major depressive disorder (In volunteers) in France (PO)
  • 28 Jan 2015 Discontinued - Phase-II for Major depressive disorder (Adjunctive treatment) in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top